Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 6, 2002, Pages 641-646

  Janssen, Marcel ^a   Oyen, Wim J G ^a   Massuger, Leon F A G ^a   Frielink, Cathelijne ^a   Dijkgraaf, Ingrid ^a   Edwards, D Scott ^b   Radjopadhye, Milind ^b   Corstens, Frans H M ^a   Boerman, Otto C ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Ovarian carcinoma; RGD peptides, v 3 integrin; Tumor targeting

Indexed keywords

ALPHA5 INTEGRIN; ARGINYLGLYCYLASPARTIC ACID; BETA3 INTEGRIN; DIMER; INTEGRIN; INTEGRIN RECEPTOR; MONOMER; RADIOISOTOPE; TECHNETIUM 99M; VITRONECTIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GYNECOLOGIC CANCER; ISOTOPE LABELING; MOUSE; NONHUMAN; OVARY CARCINOMA; PEPTIDE ANALYSIS; PRIORITY JOURNAL; RECEPTOR BINDING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TISSUE DISTRIBUTION; TUMOR GROWTH; XENOGRAFT;

EID: 0036930886     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802320970244     Document Type: Article

References (13)

1. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43:175-203.
2. vβ3 for angiogenesis. Science 1994;264:569-571.
3. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984;309:30-33.
4. Smith JW, Cheresh DA. The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffinity cross-linking implicates amino acid residues 61-203 of the beta subunit. J Biol Chem 1988;263:18726-18731.
5. 3 integrin antagonists. J Med Chem 1999;42:3033-3040.
6. 99mTc-labeling of a hydrazinoni-cotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem 2001;12:624-629.
7. 3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 1999;40:1061-1071.
8. Van Hagen PM, Breeman WA, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt MA, Krenning EP, de Jong M. Evaluation of a radiolabeled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer 2000;90:186-198.
9. Pytela R, Pierschbacher MD, Argraves S, Suzuki S, Ruoslahti E. Arginine-glycine-aspartic acid adhesion receptors. Methods Enzymol 1987;144:475-489.
10. 3 integrin directed therapeutics. Bioconjug Chem 2002;13:128-135.
11. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326-336.
12. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-212.
13. Boerman OC, Oyen WJ, Corstens FH. Between the Scylla and Charybdis of peptide radionuclide therapy: Hitting the tumor and saving the kidney. Eur J Nucl Med 2001;28:1447-1449.